相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hironobu Hashimoto et al.
LANCET ONCOLOGY (2020)
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study
Reiko Matsui et al.
BMC PHARMACOLOGY & TOXICOLOGY (2020)
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting
Kazuki Tanaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial
Cindy Weinstein et al.
SUPPORTIVE CARE IN CANCER (2018)
A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer
Reiko Sakurai et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy
Fausto Roila et al.
SUPPORTIVE CARE IN CANCER (2017)
2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents
Karin Jordan et al.
SUPPORTIVE CARE IN CANCER (2017)
A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting
Toshinobu Hayashi et al.
SUPPORTIVE CARE IN CANCER (2017)
Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin
Hideaki Yahata et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy
Paul J. Hesketh et al.
CANCER (2016)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan
Kazuo Tamura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer
Hideki Kusagaya et al.
LUNG CANCER (2015)
Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy
Yasuhiro Ito et al.
LUNG CANCER (2014)
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
M. Tanioka et al.
BRITISH JOURNAL OF CANCER (2013)
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)
M. Aapro et al.
ANNALS OF ONCOLOGY (2012)
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
Doranne L. Hilarius et al.
SUPPORTIVE CARE IN CANCER (2012)
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy
David G. Warr et al.
SUPPORTIVE CARE IN CANCER (2011)
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
Paul J. Hesketh et al.
SUPPORTIVE CARE IN CANCER (2010)
分享论文
